{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:02:01Z","timestamp":1781726521759,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"21-22","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This publication provides a\u00a0thorough analysis of the most relevant topics concerning the management of latent tuberculosis when using biologic and targeted synthetic Disease Modifying Antirheumatic Drugs (DMARDs) by a\u00a0multidisciplinary, select committee of Austrian physicians. The committee includes members of the Austrian Societies for Rheumatology and Rehabilitation, Pulmonology, Infectiology, Dermatology and Gastroenterology. Consensus was reached on issues regarding screening and treatment of latent tuberculosis and includes separate recommendations for each biologic and targeted synthetic DMARD.<\/jats:p>","DOI":"10.1007\/s00508-022-02062-7","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T08:03:07Z","timestamp":1661760187000},"page":"751-765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)"],"prefix":"10.1007","volume":"134","author":[{"given":"Eva","family":"Rath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Duftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentine","family":"Moazedi-Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Pieringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Puchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Flick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut J. F.","family":"Salzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Skvara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Moschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Feurstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-3259","authenticated-orcid":false,"given":"Judith","family":"Sautner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"2062_CR1","unstructured":"Consensus Statement 2011 \u00d6sterreichische \u00c4rztezeitung. https:\/\/infektiologie.co.at\/wp-content\/uploads\/2017\/08\/cs-tbc_u_biologika.pdf. Accessed 15\u00a0Aug 2022."},{"key":"2062_CR2","unstructured":"WHO-Global Tuberculosis Report. 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240013131. Accessed 15\u00a0Aug 2022."},{"key":"2062_CR3","unstructured":"https:\/\/www.ages.at\/themen\/krankheitserreger\/tuberkulose-tbc\/. Accessed 15\u00a0Aug 2022."},{"key":"2062_CR4","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018","unstructured":"WHO, editor. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018."},{"issue":"10","key":"2062_CR5","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven\u00a0RF, Fleischmann\u00a0RM, Furst\u00a0DE, Lacey\u00a0S, Lehane\u00a0PB. Longterm safety of Rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J\u00a0Rheumatol. 2015;42(10):1761\u20136. https:\/\/doi.org\/10.3899\/jrheum.150051.","journal-title":"J Rheumatol"},{"key":"2062_CR6","doi-asserted-by":"publisher","first-page":"1759720X2093011","DOI":"10.1177\/1759720X20930116","volume":"12","author":"G Evangelatos","year":"2020","unstructured":"Evangelatos\u00a0G, Koulouri\u00a0V, Iliopoulos\u00a0A, Fragoulis\u00a0GE. Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors. Ther Adv Musculoskelet Dis. 2020;12:1759720X20930116.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"Suppl 2","key":"2062_CR7","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","volume":"24","author":"M Mikulska","year":"2018","unstructured":"Mikulska\u00a0M, Lanini\u00a0S, Gudiol\u00a0C, Drgona\u00a0L, Ippolito\u00a0G, Fern\u00e1ndez-Ruiz\u00a0M, Salzberger\u00a0B, ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24(Suppl 2):S71\u2013S82. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.003.","journal-title":"Clin Microbiol Infect"},{"issue":"15","key":"2062_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane\u00a0J, Gershon\u00a0S, Wise\u00a0RP, Mirabile-Levens\u00a0E, Kasznica\u00a0J, Schwieterman\u00a0WD, Siegel\u00a0JN, Braun\u00a0MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N\u00a0Engl J Med. 2001;345(15):1098\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa011110.","journal-title":"N Engl J Med"},{"issue":"sup1","key":"2062_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","volume":"15","author":"S Minozzi","year":"2016","unstructured":"Minozzi\u00a0S, Bonovas\u00a0S, Lytras\u00a0T, Pecoraro\u00a0V, Gonz\u00e1lez-Lorenzo\u00a0M, Judina Bastiampillai\u00a0A, Gabrielli\u00a0EM, Lonati\u00a0AC, Moja\u00a0L, Cinquini\u00a0M, Marino\u00a0V, Matucci\u00a0A, Milano\u00a0GM, Tocci\u00a0G, Scarpa\u00a0R, Goletti\u00a0D, Cantini\u00a0F. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a\u00a0systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11\u201334. https:\/\/doi.org\/10.1080\/14740338.2016.1240783.","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 2","key":"2062_CR10","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"JW Baddley","year":"2018","unstructured":"Baddley\u00a0JW, Cantini\u00a0F, Goletti\u00a0D, G\u00f3mez-Reino\u00a0JJ, Mylonakis\u00a0E, San-Juan\u00a0R, Fern\u00e1ndez-Ruiz\u00a0M, Torre-Cisneros\u00a0J, ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor\u2011\u03b1 agents). Clin Microbiol Infect. 2018;24(Suppl 2):S10\u2013S20. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.025.","journal-title":"Clin Microbiol Infect"},{"key":"2062_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon\u00a0WG, Hyrich\u00a0KL, Watson\u00a0KD, Lunt\u00a0M, Galloway\u00a0J, Ustianowski\u00a0A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"2062_CR12","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop\u00a0KL, Mariette\u00a0X, Silva\u00a0JT, Benamu\u00a0E, Calabrese\u00a0LH, Dumusc\u00a0A, Smolen\u00a0JS, Aguado\u00a0JM, Fern\u00e1ndez-Ruiz\u00a0M, ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24(Suppl 2):S21\u2013S40. https:\/\/doi.org\/10.1016\/j.cmi.2018.02.002.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"2062_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","volume":"14","author":"F Cantini","year":"2015","unstructured":"Cantini\u00a0F, Nannini\u00a0C, Niccoli\u00a0L, Iannone\u00a0F, Delogu\u00a0G, Garlaschi\u00a0G, Sanduzzi\u00a0A, Matucci\u00a0A, Prignano\u00a0F, Conversano\u00a0M, Goletti\u00a0D. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Autoimmun Rev. 2015;14(6):503\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2015.01.011.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2062_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini\u00a0L, Lopalco\u00a0G, Caso\u00a0F, Costa\u00a0L, Iannone\u00a0F, Lapadula\u00a0G, Anelli\u00a0MG, Franceschini\u00a0R, Menicacci\u00a0C, Galeazzi\u00a0M, Selmi\u00a0C, Rigante\u00a0D. Effectiveness and tuberculosis-related safety profile of interleukin\u20111 blocking agents in the management of Beh\u00e7et\u2019s disease. Autoimmun Rev. 2015;14(1):1\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.008.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"2062_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","volume":"18","author":"F Cantini","year":"2019","unstructured":"Cantini\u00a0F, Niccoli\u00a0L, Capone\u00a0A, Petrone\u00a0L, Goletti\u00a0D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019;18(5):415\u201325. https:\/\/doi.org\/10.1080\/14740338.2019.1612872.","journal-title":"Expert Opin Drug Saf"},{"key":"2062_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/MD.0b013e3181fdd832","volume":"89","author":"L de Beaucoudrey","year":"2010","unstructured":"de Beaucoudrey\u00a0L, Samarina\u00a0A, Bustamante\u00a0J, Cobat\u00a0A, Boisson-Dupuis\u00a0S, Feinberg\u00a0J, et al. Revisiting human IL-12Rb1 deficiency: a\u00a0survey of 141\u00a0patients from 30\u00a0countries. Medicine. 2010;89:381\u2013402.","journal-title":"Medicine"},{"issue":"7","key":"2062_CR17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/art.40861","volume":"71","author":"DJ Wallace","year":"2019","unstructured":"Wallace\u00a0DJ, Ginzler\u00a0EM, Merrill\u00a0JT, Furie\u00a0RA, Stohl\u00a0W, Chatham\u00a0WW, Weinstein\u00a0A, McKay\u00a0JD, McCune\u00a0WJ, Petri\u00a0M, Fettiplace\u00a0J, Roth\u00a0DA, Ji\u00a0B, Heath\u00a0A. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(7):1125\u201334.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2062_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jdv.14015","volume":"31","author":"K Reich","year":"2017","unstructured":"Reich\u00a0K, Gooderham\u00a0M, Green\u00a0L, Bewley\u00a0A, Zhang\u00a0Z, Khanskaya\u00a0I, Day\u00a0RM, Goncalves\u00a0J, Shah\u00a0K, Piguet\u00a0V, Soung\u00a0J. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a\u00a0phase IIIb, randomized, placebo-controlled trial (LIBERATE). J\u00a0Eur Acad Dermatol Venereol. 2017;31(3):507\u201317. https:\/\/doi.org\/10.1111\/jdv.14015.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2062_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","volume":"157","author":"BE Elewski","year":"2021","unstructured":"Elewski\u00a0BE, Baddley\u00a0JW, Deodhar\u00a0AA, Magrey\u00a0M, Rich\u00a0PA, Soriano\u00a0ER, Soung\u00a0J, Bao\u00a0W, Keininger\u00a0D, Marfo\u00a0K, Patekar\u00a0M, Sharma\u00a0A, Shete\u00a0A, Lebwohl\u00a0MG. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3257. Erratum in: JAMA Dermatol. 2021 Jan 1;157(1):124.","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"2062_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000501989","volume":"11","author":"S Ribero","year":"2019","unstructured":"Ribero\u00a0S, Licciardello\u00a0M, Quaglino\u00a0P, Dapavo\u00a0P. Efficacy and safety of secukinumab in patients with plaque psoriasis and latent tuberculosis. Case Rep Dermatol. 2019;11(Suppl 1):23\u20138. https:\/\/doi.org\/10.1159\/000501989.","journal-title":"Case Rep Dermatol"},{"key":"2062_CR21","doi-asserted-by":"publisher","unstructured":"Janet G. Markle, Rub\u00e9n Mart\u013anez-Barricarte, Cindy S. Ma, Elissa K. Deenick, No\u00e9 Ram\u00edrez-Alejo, Federico Mele, Daniela Latorre, Seyed Alireza Mahdaviani, Caner Aytekin, Davood Mansouri, Vanessa Bryant, Fabienne Jabot-Hanin, Caroline Deswarte, Alejandro Nieto-Patl\u00e1n, Laura Surace, Gaspard Kerner, Yuval Itan, Sandra Jovic, Danielle T. Avery, Natalie Wong, Geetha Rao, Etienne Patin, Satoshi Okada, Benedetta Bigio, Bertrand Boisson, Franck Rapaport, Yoann Seeleuthner, Monika Schmidt, Aydan Ikinciogullari, Figen Dogu, Gonul Tanir, Payam Tabarsi, Mohammed Reza Bloursaz, Julia K. Joseph, Avneet Heer, Xiao-Fei Kong, M\u00e9lanie Migaud, Tomi Lazarov, Fr\u00e9d\u00e9ric Geissmann, Bernhard Fleckenstein, Cecilia Lindestam Arlehamn, Alessandro Sette, Anne Puel, Jean-Fran\u00e7ois Emile, Esther van de Vosse, Lluis Quintana-Murci, James P. Di Santo, Laurent Abel, St\u00e9phanie Boisson-Dupuis, Jacinta Bustamante, Stuart G. Tangye, Federica Sallusto, Jean-Laurent Casanova. Human IFN\u2011\u03b3 immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol. Author manuscript; available in PMC 2019 Jun 21. Published in final edited form as: Sci Immunol. 2018 Dec 21; 3(30): eaau6759. https:\/\/doi.org\/10.1126\/sciimmunol.aau6759","DOI":"10.1126\/sciimmunol.aau6759"},{"issue":"4","key":"2062_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/jdv.16866","volume":"35","author":"M Nogueira","year":"2021","unstructured":"Nogueira\u00a0M, Warren\u00a0RB, Torres\u00a0T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis\u2014time for a\u00a0paradigm change. J\u00a0Eur Acad Dermatol Venereol. 2021;35(4):824\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2062_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop\u00a0KL, Park\u00a0SH, Gul\u00a0A, Cardiel\u00a0MH, Gomez-Reino\u00a0JJ, Tanaka\u00a0Y, Kwok\u00a0K, Lukic\u00a0T, Mortensen\u00a0E, Ponce de Leon\u00a0D, Riese\u00a0R, Valdez\u00a0H. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2062_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14740338.2020.1774550","volume":"19","author":"F Cantini","year":"2020","unstructured":"Cantini\u00a0F, Blandizzi\u00a0C, Niccoli\u00a0L, Petrone\u00a0L, Goletti\u00a0D. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf. 2020;19(7):861\u201372.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2062_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt\u00a0J, Lee\u00a0EB, Curtis\u00a0JR, Silverfield\u00a0J, Terry\u00a0K, Soma\u00a0K, Mojcik\u00a0C, DeMasi\u00a0R, Strengholt\u00a0S, Kwok\u00a0K, Lazariciu\u00a0I, Wang\u00a0L, Cohen\u00a0S. Safety and efficacy of tofacitinib for up to 9.5\u00a0years in the treatment of rheumatoid arthritis: final results of a\u00a0global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. https:\/\/doi.org\/10.1186\/s13075-019-1866-2.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"2062_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/jbmr.3119","volume":"32","author":"NB Watts","year":"2017","unstructured":"Watts\u00a0NB, Brown\u00a0JP, Papapoulos\u00a0S, Lewiecki\u00a0EM, Kendler\u00a0DL, Dakin\u00a0P, Wagman\u00a0RB, Wang\u00a0A, Daizadeh\u00a0NS, Smith\u00a0S, Bone\u00a0HG. Safety observations with 3 years of denosumab exposure: comparison between subjects who received denosumab during the randomized FREEDOM trial and subjects who crossed over to Denosumab during the FREEDOM extension. J\u00a0Bone\u00a0Miner Res. 2017;32(7):1481\u20135. https:\/\/doi.org\/10.1002\/jbmr.3119.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2062_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/1744-9987.12788","volume":"23","author":"A Torres-Ortiz","year":"2019","unstructured":"Torres-Ortiz\u00a0A, Acharya\u00a0P, Cheungpasitporn\u00a0W. Successful treatment of tuberculosis-associated hypercalcemia with denosumab in a\u00a0patient with acute kidney injury. Ther Apher Dial. 2019;23(5):484\u20135.","journal-title":"Ther Apher Dial"},{"issue":"11","key":"2062_CR28","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","volume":"39","author":"S Kaveh","year":"2020","unstructured":"Kaveh\u00a0S, Hosseinifard\u00a0H, Ghadimi\u00a0N, Vojdanian\u00a0M, Aryankhesal\u00a0A. Efficacy and safety of Romosozumab in treatment for low bone mineral density: a\u00a0systematic review and meta-analysis. Clin Rheumatol. 2020;39(11):3261\u201376. https:\/\/doi.org\/10.1007\/s10067-020-04948-1.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2062_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel\u00a0JF, Sands\u00a0BE, Rutgeerts\u00a0P, Sandborn\u00a0W, Danese\u00a0S, D\u2019Haens\u00a0G, Panaccione\u00a0R, Loftus\u00a0EV Jr, Sankoh\u00a0S, Fox\u00a0I, Parikh\u00a0A, Milch\u00a0C, Abhyankar\u00a0B, Feagan\u00a0BG. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351.","journal-title":"Gut"},{"issue":"7","key":"2062_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ, Bekker\u00a0P, ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N\u00a0Engl J Med. 2021;384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386.","journal-title":"N Engl J Med"},{"issue":"26","key":"2062_CR31","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro\u00a0M, Corren\u00a0J, Pavord\u00a0ID, Maspero\u00a0J, Wenzel\u00a0S, Rabe\u00a0KF, Busse\u00a0WW, Ford\u00a0L, Sher\u00a0L, FitzGerald\u00a0JM, Katelaris\u00a0C, Tohda\u00a0Y, Zhang\u00a0B, Staudinger\u00a0H, Pirozzi\u00a0G, Amin\u00a0N, Ruddy\u00a0M, Akinlade\u00a0B, Khan\u00a0A, Chao\u00a0J, Martincova\u00a0R, Graham\u00a0NMH, Hamilton\u00a0JD, Swanson\u00a0BN, Stahl\u00a0N, Yancopoulos\u00a0GD, Teper\u00a0A. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N\u00a0Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"issue":"7","key":"2062_CR32","doi-asserted-by":"publisher","first-page":"e0235488","DOI":"10.1371\/journal.pone.0235488","volume":"15","author":"V Taneja","year":"2020","unstructured":"Taneja\u00a0V, Kalra\u00a0P, Goel\u00a0M, Khilnani\u00a0GC, Saini\u00a0V, Prasad\u00a0GBKS, Gupta\u00a0UD, Prasad\u00a0KH. Impact and prognosis of the expression of IFN\u2011\u03b1 among tuberculosis patients. PLoS ONE. 2020;15(7):e235488. https:\/\/doi.org\/10.1371\/journal.pone.0235488.","journal-title":"PLoS ONE"},{"key":"2062_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3389\/fimmu.2017.01633","volume":"8","author":"ML Donovan","year":"2017","unstructured":"Donovan\u00a0ML, Schultz\u00a0TE, Duke\u00a0TJ, Blumenthal\u00a0A. Type I Interferons in the pathogenesis of tuberculosis: molecular drivers and immunological consequences. Front Immunol. 2017;8:1633. https:\/\/doi.org\/10.3389\/fimmu.2017.01633.","journal-title":"Front Immunol"},{"key":"2062_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1186\/s12879-019-4654-3","volume":"19","author":"J Wang","year":"2019","unstructured":"Wang\u00a0J, Hussain\u00a0T, Zhang\u00a0K, et\u00a0al. Inhibition of type I interferon signaling abrogates early Mycobacterium bovis infection. BMC Infect Dis. 2019;19:1031. https:\/\/doi.org\/10.1186\/s12879-019-4654-3.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2062_CR35","doi-asserted-by":"publisher","first-page":"e000464","DOI":"10.1136\/lupus-2020-000464","volume":"8","author":"R Tummala","year":"2021","unstructured":"Tummala\u00a0R, Abreu\u00a0G, Pineda\u00a0L, Michaels\u00a0MA, Kalyani\u00a0RN, Furie\u00a0RA, Morand\u00a0EF. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021;8(1):e464. https:\/\/doi.org\/10.1136\/lupus-2020-000464.","journal-title":"Lupus Sci Med"},{"issue":"1","key":"2062_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling\u00a0TR, Njie\u00a0G, Zenner\u00a0D, Cohn\u00a0DL, Reves\u00a0R, Ahmed\u00a0A, Menzies\u00a0D, Horsburgh\u00a0CR Jr, Crane\u00a0CM, Burgos\u00a0M, LoBue\u00a0P, Winston\u00a0CA, Belknap\u00a0R. Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC. MMWR Recomm Rep. 2020;69(1):1\u201311. https:\/\/doi.org\/10.15585\/mmwr.rr6901a1.","journal-title":"MMWR Recomm Rep"},{"key":"2062_CR37","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018","unstructured":"WHO, editor. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"2062_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1055\/s-0043-105954","volume":"71","author":"T Schaberg","year":"2017","unstructured":"Schaberg\u00a0T, et al. 2Sk-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie. 2017;71:325\u201397. https:\/\/doi.org\/10.1055\/s-0043-105954.","journal-title":"Pneumologie"},{"key":"2062_CR39","doi-asserted-by":"publisher","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Mill\u00e1n I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 Jul;73(7):1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752. Epub 2021 Jun 8. PMID: 34101376.","DOI":"10.1002\/art.41752"},{"issue":"1","key":"2062_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12955-017-0754-1","volume":"15","author":"A Darzi","year":"2017","unstructured":"Darzi\u00a0A, Harfouche\u00a0M, Arayssi\u00a0T, Alemadi\u00a0S, Alnaqbi\u00a0KA, Badsha\u00a0H, Al Balushi\u00a0F, Elzorkany\u00a0B, Halabi\u00a0H, Hamoudeh\u00a0M, Hazer\u00a0W, Masri\u00a0B, Omair\u00a0MA, Uthman\u00a0I, Ziade\u00a0N, Singh\u00a0JA, Christiansen\u00a0R, Tugwell\u00a0P, Sch\u00fcnemann\u00a0HJ, Akl\u00a0EA. Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. Health Qual Life Outcomes. 2017;15(1):183. https:\/\/doi.org\/10.1186\/s12955-017-0754-1. Erratum in: Health Qual Life Outcomes. 2017 Oct 26;15(1):214.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"2062_CR41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bijlsma\u00a0JWJ, Burmester\u00a0GR, Dougados\u00a0M, Kerschbaumer\u00a0A, McInnes\u00a0IB, Sepriano\u00a0A, van Vollenhoven\u00a0RF, de Wit\u00a0M, Aletaha\u00a0D, Aringer\u00a0M, Askling\u00a0J, Balsa\u00a0A, Boers\u00a0M, den Broeder\u00a0AA, Buch\u00a0MH, Buttgereit\u00a0F, Caporali\u00a0R, Cardiel\u00a0MH, De Cock\u00a0D, Codreanu\u00a0C, Cutolo\u00a0M, Edwards\u00a0CJ, van Eijk-Hustings\u00a0Y, Emery\u00a0P, Finckh\u00a0A, Gossec\u00a0L, Gottenberg\u00a0JE, Hetland\u00a0ML, Huizinga\u00a0TWJ, Koloumas\u00a0M, Li\u00a0Z, Mariette\u00a0X, M\u00fcller-Ladner\u00a0U, Mysler\u00a0EF, da Silva\u00a0JAP, Po\u00f3r\u00a0G, Pope\u00a0JE, Rubbert-Roth\u00a0A, Ruyssen-Witrand\u00a0A, Saag\u00a0KG, Strangfeld\u00a0A, Takeuchi\u00a0T, Voshaar\u00a0M, Westhovens\u00a0R, van der Heijde\u00a0D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2062_CR42","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0R, Breedveld\u00a0FC, Buch\u00a0M, Burmester\u00a0G, Dougados\u00a0M, Emery\u00a0P, Gaujoux-Viala\u00a0C, Gossec\u00a0L, Nam\u00a0J, Ramiro\u00a0S, Winthrop\u00a0K, de Wit\u00a0M, Aletaha\u00a0D, Betteridge\u00a0N, Bijlsma\u00a0JW, Boers\u00a0M, Buttgereit\u00a0F, Combe\u00a0B, Cutolo\u00a0M, Damjanov\u00a0N, Hazes\u00a0JM, Kouloumas\u00a0M, Kvien\u00a0TK, Mariette\u00a0X, Pavelka\u00a0K, van Riel\u00a0PL, Rubbert-Roth\u00a0A, Scholte-Voshaar\u00a0M, Scott\u00a0DL, Sokka-Isler\u00a0T, Wong\u00a0JB, van der Heijde\u00a0D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204573.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2062_CR43","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","volume":"58","author":"CR Holroyd","year":"2019","unstructured":"Holroyd\u00a0CR, Seth\u00a0R, Bukhari\u00a0M, Malaviya\u00a0A, Holmes\u00a0C, Curtis\u00a0E, Chan\u00a0C, Yusuf\u00a0MA, Litwic\u00a0A, Smolen\u00a0S, Topliffe\u00a0J, Bennett\u00a0S, Humphreys\u00a0J, Green\u00a0M, Ledingham\u00a0J. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Baillieres Clin Rheumatol. 2019;58(2):e3\u2013e42. https:\/\/doi.org\/10.1093\/rheumatology\/key208. Erratum in: Rheumatology (Oxford). 2019 Feb 1;58(2):372.","journal-title":"Baillieres Clin Rheumatol"},{"key":"2062_CR44","first-page":"1092","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast\u00a0A, et\u00a0al. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm \u2013 Teil 1: Therapieziele und Therapieempfehlungen. J Dtsch Dermatol Ges. 2021;19:1092\u2013117.","journal-title":"J Dtsch Dermatol Ges"},{"key":"2062_CR45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1183\/09031936.00151309","volume":"36","author":"CBE Chee","year":"2010","unstructured":"Chee\u00a0CBE, Khinmar\u00a0KW, Gan\u00a0SH, Barkham\u00a0TM, Koh\u00a0CK, Shen\u00a0L, Wang\u00a0YT. Tuberculosis treatment effect on T\u2011cell interferon\u2011\u03b3 responses to Mycobacterium tuberculosis-specific antigens. Eur Respir\u00a0J. 2010;36:355\u201361. https:\/\/doi.org\/10.1183\/09031936.00151309.","journal-title":"Eur Respir J"},{"key":"2062_CR46","unstructured":"homepage of the Austrian Agency for Health and Food Safety (AGES) 2022-04-15. https:\/\/www.ages.at\/en\/mensch\/krankheit\/krankheitserreger-von-a-bis-z\/tuberkulose?sword_list%5B0%5D=tuberculosis&no_cache=1. Accessed 15\u00a0Aug 2022."}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02062-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-022-02062-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-022-02062-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:15:12Z","timestamp":1669299312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-022-02062-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":46,"journal-issue":{"issue":"21-22","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1007\/s00508-022-02062-7","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"27 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.\u00a0Rath, M.\u00a0Bonelli, C.\u00a0Duftner, J.\u00a0Gruber, P.\u00a0Mandl, F.\u00a0Moazedi-Furst, H.\u00a0Pieringer, R.\u00a0Puchner, H.\u00a0Flick, H.J.F.\u00a0Salzer, G.\u00a0Weiss, S.\u00a0Winkler, H.\u00a0Skvara, A.\u00a0Moschen, H.\u00a0Hofer, J.\u00a0Feurstein and J.\u00a0Sautner declare that they have no competing interests; the project was planned and carried out without any sponsoring.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}